MORGAN STANLEY PLC/PUT/ELI LILLY & CO/750/0.01/17.01.25 | Market Closed - Börse Stuttgart 09:41:41 10/07/2024 pm IST | ||
| 0.16 EUR | -6.43% |
|
| Current month | -17.53% | ||
| 1 month | -42.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 10/24/10 | 0.16 | -6.43% |
| 09/24/09 | 0.171 | -6.04% |
| 08/24/08 | 0.182 | -5.70% |
| 05/24/05 | 0.193 | -12.67% |
| 04/24/04 | 0.221 | -4.74% |
Delayed Quote Börse Stuttgart
Last update July 10, 2024 at 09:41 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME8H0N |
| ISIN | DE000ME8H0N9 |
| Date issued | 09/02/2024 |
| Strike | 750 $ |
| Maturity | 17/01/2025 (191 Days) |
| Parity | 100 : 1 |
| Emission price | 0.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.81 € |
|---|---|
| Lowest since issue | 0.16 € |
| Spread | 0.009 € |
| Spread % | 4.95% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
939.8
USD
Average target price
874.8
USD
Spread / Average Target
-6.92%
- Stock Market
- Warrants
- Warrant
